Loading…
Agios Pharmaceuticals, Inc. is projected to rise to $35.15 by 2027, a +23% move from its current price of $28.62. AGIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $27.91 | $28.62 | $29.35 | 0.00% |
| May 30 | $27.62 | $28.62 | $29.66 | +0.01% |
| May 31 | $27.41 | $28.62 | $29.89 | +0.01% |
| Jun 1 | $27.22 | $28.62 | $30.10 | +0.01% |
| Jun 2 | $27.06 | $28.63 | $30.28 | +0.02% |
| Jun 3 | $26.92 | $28.63 | $30.44 | +0.02% |
| Jun 4 | $26.79 | $28.63 | $30.59 | +0.03% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.79 | $28.63 | $30.59 | +0.03% |
| Week 2 | $26.07 | $28.63 | $31.45 | +0.05% |
| Week 3 | $25.53 | $28.64 | $32.13 | +0.08% |
| Week 4 | $25.09 | $28.65 | $32.72 | +0.10% |
| Week 5 | $24.70 | $28.66 | $33.24 | +0.13% |
| Week 6 | $24.36 | $28.66 | $33.72 | +0.15% |
| Week 7 | $24.05 | $28.67 | $34.17 | +0.18% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Agios Pharmaceuticals, Inc. is a United States-based biopharmaceutical company that discovers and develops medicines in the field of cellular metabolism.
Its lead product PYRUKYND (mitapivat) is an activator of wild-type and mutant pyruvate kinase (PK) enzymes, used for the treatment of hemolytic anemias in adults with PK deficiency. The PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
Agios was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AGIO is a healthcare stock currently priced at $28.14 with a market cap of $1.67B and a rank of 2140. The stock resides in the Healthcare sector and reflects exposure to a biopharmaceutical landscape characterized by development-stage programs and commercial products. The forecast shows a long-run bullish trajectory, with the average price rising from $28.14 in 2026 toward substantially higher levels by 2030 and beyond, accompanied by notable upside in the max forecasts.
By 2030 the avg is $59.66 with a max of $86.56 and an ROI of 112, and by 2050 the avg is $332.07 with a max of $608.40 and an ROI of 1080.1, illustrating a strong long-run upside under the provided assumptions.
The forecast also highlights a neutral stance in 2026, transitioning to bullish sentiment in later years, with progressively higher average prices and upside potential through 2050.
A major floor 34.7% below — a decisive break under it would weaken the trend.
The nearest floor, 14.6% below — buyers have tended to step in here.
The nearest ceiling, 22.8% above — a clean break opens room to run.
A major ceiling 40.1% above — clearing it would confirm fresh momentum.
Key AGIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AGIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $28.48 | Buy | $28.42 | Buy |
| MA 10 | $28.40 | Buy | $28.32 | Buy |
| MA 20 | $28.08 | Buy | $28.35 | Buy |
| MA 50 | $29.47 | Sell | $28.82 | Sell |
| MA 100 | $28.81 | Sell | $29.55 | Sell |
| MA 200 | $32.36 | Sell | $31.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.97 | Neutral |
| Stoch RSI (14) | 87.98 | Sell |
| CCI (20) | 91.25 | Neutral |
| Williams %R (14) | -13.49 | Info |
| MACD (12,26,9) | 0.17 | Buy |
| ROC (12) | 2.99 | Buy |
| Bollinger %B (20,2) | 0.77 | Neutral |
| Stochastic %K (14) | 86.51 | Sell |
| TRIX (15) | -0.21 | Sell |
| Awesome (5,34) | -0.31 | Sell |
| Ultimate (7,14,28) | 57.28 | Neutral |
| Momentum (10) | 0.20 | Buy |
| Aroon Osc (25) | 72.00 | Buy |
| Hull MA (9) | 28.47 | Buy |
| ADX (14) | 11.00 | Neutral |
| ATR (14) | 0.54 | Info |
The near-term technical picture shows bullish sentiment with RSI14 at 50. The 50-day moving average is $29.47 and the 200-day moving average is $32.44, framing near-term price dynamics.
Support is identified at $24.43 and resistance at $35.14, forming the core near-term levels to watch. The 30-day price range spans from $23.62 to $33.53, indicating current volatility within a defined corridor.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $24.43 | $28.62 | $36.71 | 0% | Neutral | |
| $28.09 | $35.15 | $46.45 | +23% | Bullish | |
| $30.69 | $39.35 | $53.75 | +37% | Bullish | |
| $37.48 | $49.06 | $68.81 | +71% | Bullish | |
| $46.19 | $61.58 | $88.31 | +115% | Bullish | |
| $48.53 | $65.78 | $96.20 | +130% | Bullish | |
| $54.29 | $74.75 | $111.25 | +161% | Bullish | |
| $57.19 | $79.90 | $120.83 | +179% | Bullish | |
| $56.42 | $79.91 | $122.64 | +179% | Bullish | |
| $70.65 | $101.40 | $157.78 | +254% | Bullish | |
| $98.76 | $150.48 | $248.06 | +426% | Bullish | |
| $206.81 | $348.96 | $626.04 | +11.2x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $24.43 | $28.62 | $33.73 | +0.00% |
| June 2026 | $24.92 | $29.22 | $35.03 | +2.08% |
| July 2026 | $24.31 | $28.71 | $34.85 | -1.72% |
| August 2026 | $24.32 | $28.91 | $35.42 | +0.67% |
| September 2026 | $24.64 | $29.43 | $36.35 | +1.81% |
| October 2026 | $24.05 | $28.86 | $35.89 | -1.94% |
| November 2026 | $23.51 | $28.32 | $35.45 | -1.85% |
| December 2026 | $24.11 | $29.16 | $36.71 | +2.95% |
Click any year to see its month-by-month AGIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Agios Pharmaceuticals, Inc.'s 2026 outlook centres on $28.62, within a $24.43 to $36.71 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, AGIO could reach as high as $46.45, with a base case around $35.15 and support toward $28.09 — roughly +23% from $28.62. Momentum favours further upside here.
Expect AGIO to range from $30.69 to $53.75 through 2028. The $39.35 average target implies a +37% move from current prices. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The AGIO price prediction for 2029 points to an average of $49.06 (low $37.48, high $68.81) — a potential gain of +71% on today's $28.62. Momentum favours further upside here.
In 2030, AGIO is projected to trade between $46.19 and $88.31, averaging $61.58 — a potential gain of +115% from today's $28.62. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Agios Pharmaceuticals, Inc.'s 2031 outlook centres on $65.78, within a $48.53 to $96.20 range. That is up +7% on the projected 2030 average. That marks a +130% change versus current levels. Momentum favours further upside here.
By 2032, AGIO could reach as high as $111.25, with a base case around $74.75 and support toward $54.29 — roughly +161% from $28.62. Buyers look set to stay in control over this stretch.
Expect AGIO to range from $57.19 to $120.83 through 2033. The $79.90 average target implies a +179% move from current prices. That is up +7% on the projected 2032 average. Momentum favours further upside here.
The AGIO price prediction for 2034 points to an average of $79.91 (low $56.42, high $122.64) — a potential gain of +179% on today's $28.62. Buyers look set to stay in control over this stretch.
In 2035, AGIO is projected to trade between $70.65 and $157.78, averaging $101.40 — a potential gain of +254% from today's $28.62. That is up +27% on the projected 2034 average. Momentum favours further upside here.
Agios Pharmaceuticals, Inc.'s 2040 outlook centres on $150.48, within a $98.76 to $248.06 range. That is up +48% on the projected 2035 average. That marks a +426% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, AGIO could reach as high as $626.04, with a base case around $348.96 and support toward $206.81 — roughly +11.2x from $28.62. Momentum favours further upside here.
Investing $1,000 in AGIO today (≈ 34.940601 AGIO) could be worth
$12,193.03
+$11,193.03 (+1119%) by 2050 · US Dollar
Based on the average projected AGIO price of $348.96 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AGIOwould be worth at today's price.
$1,000 invested in AGIO on May 27, 2025 (≈ 33.112582 AGIO) would be worth
$947.68
-$52.32 (-5.2%) today · 0.95× · US Dollar
Based on a AGIO entry price of $30.2 vs. today's $28.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $28.5 | $1,004.21 | +0.4% |
| 1 month ago | $24.43 | $1,171.51 | +17.2% |
| 3 months ago | $29.98 | $954.64 | -4.5% |
| 6 months ago | $29.2 | $980.14 | -2.0% |
| 1 year ago | $30.2 | $947.68 | -5.2% |
| All time (5.0y) ago | $55.87 | $512.26 | -48.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AGIO forecast.
Our base-case forecast reaches $57.00 around 2030.
Implied market cap at $57.00: $3.39B
The multi-year forecast depicts a persistently bullish path after 2026, with 2026 labeled as neutral and subsequent years showing stronger upside.
By 2030 the average price is projected at $59.66, with a maximum of $86.56 and an ROI of 112. The year 2031 shows an average of $63.71 with an ROI of 126.4, and 2032 shows an average of $72.24 with an ROI of 156.7. The trajectory continues through 2033 ($76.23, ROI 170.9) and 2034 ($76.02, ROI 170.2) before 2035 ($97.57, ROI 246.7).
Looking further ahead, 2040 carries an average of $142.36 with an ROI of 405.9, and 2050 presents an average of $332.07 with an ROI of 1080.1 and a max of $608.40. Across years, the sentiment remains BULLISH, while the forecast notes substantial upside potential and inherent uncertainty.
Tap a question to reveal the answer.
In 2030 the forecast shows an average price of $59.66, with a minimum of $44.31 and a maximum of $86.56, and an ROI of 112. The sentiment for that year is BULLISH.
The forecast indicates neutral in 2026 but bullish from 2027 onward, with rising average prices and meaningful upside in later years (e.g., avg $59.66 by 2030 and avg $332.07 by 2050, with higher max prices). These are estimates and carry uncertainty.
Yes. The max forecast reaches $154.17 in 2035 and climbs to higher levels, with $238.87 max in 2040 and $608.40 max in 2050, indicating potential to surpass $100 in the horizon shown.
The current price is $28.14 and the market cap is $1.67B. The stock has a rank of 2140.
The near-term picture is bullish with RSI at 50. The 50-day and 200-day moving averages are $29.47 and $32.44 respectively. Support sits at $24.43 and resistance at $35.14, with a 30-day range of $23.62 to $33.53.
Agios Pharmaceuticals, Inc. Community Discussion
0Share your Agios Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.